Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2024-12-13 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：第三届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Shanghai Medicilon Inc. It details the convening of the board meeting, attendance, and the approval of a specific proposal related to the cancellation of certain unvested restricted stock awards from 2020. The document includes voting results and references compliance with company law and internal governance rules. There is no financial data, earnings information, or detailed report content. The document is clearly an announcement of board/management decisions, specifically about stock incentive plan adjustments, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or financial statement itself, but a formal announcement of board resolutions.
2024-12-13 Chinese
北京安理（上海）律师事务所关于上海美迪西生物医药股份有限公司2020年限制性股票激励计划作废部分已授予尚未归属的限制性股票的法律意见书
Regulatory Filings
2024-12-13 Chinese
美迪西：关于作废部分已授予尚未归属的2020年限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shanghai Medicilon Inc. regarding the cancellation of part of the 2020 restricted stock awards that have been granted but not yet vested. It details the board and supervisory committee meetings approving this cancellation, references the stock incentive plan, and discusses compliance with relevant laws and regulations. The document is a formal disclosure about a change in the company's equity incentive plan, specifically the cancellation of unvested restricted shares. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a report like an annual or interim report, nor is it a call transcript or audit report. It is a regulatory announcement about a corporate action related to equity incentives. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-12-13 Chinese
美迪西：关于董事会、监事会延期换届的提示性公告
Board/Management Information Classification · 100% confidence The document is a public announcement from Shanghai Medicilon Inc. regarding the postponement of the board of directors and supervisory board re-election. It discusses the extension of the current board and management terms to ensure continuity and stability. There is no financial data, no mention of financial results, no audit information, no voting results, and no regulatory certifications. The content is about management and board changes, specifically the delay in board re-election. This fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a direct announcement about management changes.
2024-11-20 Chinese
美迪西：关于召开2024年第三季度业绩说明会的公告
Call Transcript Classification · 70% confidence The document is an announcement about the scheduling and details of a 2024 third quarter earnings explanation meeting (业绩说明会). It mentions the date, time, location, participants, and how investors can participate and ask questions. It references the company's 2024 third quarter report already published on October 31, 2024, but this document itself does not contain financial data or the report itself. It is a notice about an upcoming earnings call or presentation event rather than the transcript or the report. Given the nature of the document as an announcement for an earnings explanation meeting, it fits best under the category of Call Transcript (CT) or Investor Presentation (IP). However, since it is only an announcement of the meeting and not the transcript or presentation itself, and it is not a simple report publication announcement, the closest category is Call Transcript (CT) because it is about an earnings explanation meeting. The document length is short (1556 characters), and it is not the transcript but an announcement of the meeting. According to the rules, announcements of meetings are not specifically listed, but since it is about an earnings explanation meeting, the best fit is Call Transcript (CT) with moderate confidence. However, since it is only an announcement and not the transcript, the fallback is Regulatory Filings (RNS). But the document is more specific than a generic regulatory filing because it is about an earnings explanation meeting. Therefore, the best classification is Call Transcript (CT) with confidence 0.7.
2024-11-11 Chinese
美迪西：关于股东股份被司法冻结的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shanghai Medicilon Inc. regarding the judicial freezing of shares held by a shareholder named Chen Guoxing. It details the number of shares frozen, the percentage of total shares, the freezing period, and the fact that this shareholder is not a controlling shareholder. The document does not contain financial statements, audit information, or detailed financial data. It is a regulatory announcement about a shareholder's share status and legal situation. It is not a report, earnings release, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2024-10-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.